The Canadian Cancer Trials Group Central Operations and Statistics Centre will be closed on Monday, February 19, 2018 for Family Day. Regular business hours will resume on Tuesday, February 20 at 8:30 am EDT.
Published: May 30, 2017
The CCTG Accrual Utility is launched for member sites

The development team from left to right: Corey Willman, Teddy Brown, Patti O'Brien, David Judd, Heather Ritter

The CCTG Accrual Utility Team reached their final project milestone with the official launch of the Accrual Utility late last week. The customized, web-based application was developed by our in-house project team, who worked together to bring this anticipated solution to life.

Published: May 11, 2017
The trial is changing how brain cancer is treated in older patients around the world

Dr Christopher O’Callaghan knows the impact that glioblastoma, an aggressive form of brain cancer, can have on families. His father was diagnosed at a time when the only available treatment was radiation. But now, thanks to Dr O’Callaghan’s research with the Canadian Cancer Trials Group (CCTG), there are better treatment options for patients with glioblastoma.

Published: May 11, 2017
The trial is changing how brain cancer is treated in older patients around the world

Pictured here: Dr Chris O’Callaghan, senior investigator with Dr Janet Dancey, director, Canadian Cancer Trials Group

Dr Christopher O’Callaghan knows the impact that glioblastoma, an aggressive form of brain cancer, can have on families. His father was diagnosed at a time when the only available treatment was radiation. But now, thanks to Dr O’Callaghan’s research with the Canadian Cancer Trials Group (CCTG), there are better treatment options for patients with glioblastoma.

Published: May 08, 2017
CCS has renewed its commitment to CCTG through a major funding award of $23.5 million over 5 years.

From left to right: Janet Dancey, CCTG Director; Lynne Hudson, CCS President, and CEO; Richard Reznick, Dean of the Faculty of Health Sciences at Queen’s University.

The Canadian Cancer Society (CCS) has renewed its commitment to the Canadian Cancer Trials Group (CCTG) through a major funding award of $23.5 million over 5 years. This generous funding allows CCTG to continue its world-class cancer clinical trials research.

Published: April 05, 2017
Thanks to the Tragically Hip for their support of brain cancer research

Gord Sinclair, from left, and Rob Baker of The Tragically Hip, Janet Dancy, director of the Canadian Cancer Trials Group, and Lynne Hudson, president and CEO of the Canadian Cancer Society, at the unveiling of a plaque honouring The Hip.

The Canadian Cancer Society (CCS) recognized Kingston hometown heroes the Tragically Hip for their support of brain cancer research. A commemorative plaque was presented to the band in honour of their support for cancer clinical trials at the Canadian Cancer Trials Group (CCTG).

CCTG, housed at Queen’s University in Kingston, is supported by a core grant from the Canadian Cancer Society.

Published: March 02, 2017
iRECIST - immunotherapy Response Evaluation Criteria in Solid Tumours

Immunotherapeutics trigger different response patterns in tumours than classic chemotherapy drugs.

A recent publication in The Lancet Oncology highlights the development, led by the RECIST Working Group, of iRECIST (immunotherapy Response Evaluation Criteria in Solid Tumours) consensus-based guideline, which addresses the novel characteristics of this new class of anticancer therapeutics, ensuring consistent trial design and data collection.

Published: February 09, 2017

Effect of Radiotherapy on Painful Bone Metastases: A Secondary Analysis of the Canadian Clinical Trials Group Symptom Control Trial SC.23

Published: December 15, 2016

Dr. Rosalyn Juergens, the study chair of IND.226, gave an oral presentation of the experience to date on IND.226

Published: November 30, 2016

Two Canadian Cancer Trials Group (CCTG) Investigational New Drug (IND) trials – IND.221 and IND.226 – were presented today at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium in Munich, Germany.

Published: September 28, 2016

A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women with Endocrine Responsive Breast Cancer who Desire Pregnancy.